Featured Content

Latest Press Releases

Oct 25, 2021 MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Oct 22, 2021 Horizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021
Oct 21, 2021 Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)

See All Press Releases

Statements

Our Commitment to Anti-Racism

Named Patient Use Programs

Named Patient Use Program for TEPEZZA® (teprotumumab-trbw)
Named Patient Use Program for UPLIZNA® (inebilizumab-cdon)

Featured Videos

The Horizon Story

The Horizon Story

Deidre Lindsey

Deidre Lindsey

#RAREis: Francis’ Rare Disease Adoption Story in Song

#RAREis: Francis’ Rare Disease Adoption Story in Song

Giving Back is Personal

Giving Back is Personal

Corporate Brochure

Corporate Brochure

Fact Sheets & Downloads

See All Fact Sheets

Logo Download

Download Horizon Logo | RGB Full Color (.jpg)
Download Horizon Logo | RGB Full Color (.png)
Download Horizon Logo | Charcoal Single Color (.jpg)
Download Horizon Logo | Charcoal Single Color (.png)

If you are looking for additional Horizon media assets, please contact corpcomms@horizontherapeutics.com

Media Inquiries

For U.S. media inquiries, contact:
Geoff Curtis
Senior Vice President, Corporate Affairs
media@horizontherapeutics.com
+1 (888) 506-2562

For EU media inquiries, contact:
Ray Gordon
Managing Director
ray@gordonmrm.ie
+353 (87) 2417373